Is Methotrexate Therapy for Psoriasis Carcinogenic?
- 28 April 1975
- journal article
- research article
- Published by American Medical Association (AMA)
- Vol. 232 (4) , 359-362
- https://doi.org/10.1001/jama.1975.03250040013017
Abstract
The use of methotrexate in psoriasis has recently been questioned because of possible carcinogenic potential. Two hundred twenty-four patients began methotrexate therapy during 1960 to 1965 at the Cleveland Clinic and at Duke University Medical Center. The incidence of malignant neoplasms and mortality has been studied in 205 of these 224 patients. Mortality increased with hepatic disease. No increased incidence of total internal malignancy was found, nor did any one type of neoplasm appear predominant. (JAMA232:359-362, 1975)Keywords
This publication has 7 references indexed in Scilit:
- MALIGNANT TUMORS ARISING DE NOVO IN IMMUNOSUPPRESSED ORGAN TRANSPLANT RECIPIENTSTransplantation, 1972
- IMMUNOREGULATION, ONCOGENIC VIRUSES, AND MALIGNANT LYMPHOMASThe Lancet, 1972
- Methotrexate Hepatotoxicity in Psoriasis--Comparison of Different Dose RegimensBMJ, 1972
- Psoriasis, Methotrexate, and CancerArchives of Dermatology, 1972
- Immunological Surveillance in NeoplasiaImmunological Reviews, 1971
- Occurrence of malignancy in immunodeficiency diseases: A literature reviewCancer, 1971
- Immunologic Competence of Patients With Psoriasis Receiving Cytotoxic Drug TherapyArchives of Dermatology, 1965